Stock Detail
DR REDDYS LABORATORIES LTD
Sector: Drug Manufacturers Other
Latest Quote @ Fri May 5 14:56:34 (15 min delayed)
| $37.56 |
$37.60 |
$37.57 |
+0.25 |
0.67% |
|
Last Day's Data
| $37.32 |
$37.49 |
$0.00 |
0.00% |
0.23 |
$37.49 |
| $37.10 |
$36.88 |
211,618.00 |
6.34B |
236,864.00 |
20.10 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 37.84 |
37.58 |
37.23 |
36.97 |
36.62 |
Stock Profile
Dr. Reddy's Laboratories Limited engages in the development, manufacture, and marketing of pharmaceutical products. The company produces finished dosage forms, active pharmaceutical ingredients, diagnostic kits, critical care products, and biotechnology products. It also conducts research in the areas of cancer, diabetes, cardiovascular diseases, inflammation, and bacterial infection. Dr. Reddy's Laboratories sells its products in approximately 100 countries worldwide, including the United States, Russia and other European countries, India, and China. The company has strategic alliances with Par Pharmaceuticals, Inc.; Leiner Health Products, LLC; Cobalt Pharmaceuticals, Inc.; and Pharmascience, Inc. Dr Reddy's Laboratories has a co-development and commercialization agreement with Rheoscience A/S for the joint development and commercialization of balaglitazone (DRF 2593), a partial PPAR gamma agonist, for the treatment of type 2 diabetes. The company was founded by K. Anji Reddy in 1984. Dr. Reddy's Laboratories is headquartered in Hyderabad, India.
